ATE428708T1 - Neue phthalazinonderivate als aurora-a- kinaseinhibitoren - Google Patents

Neue phthalazinonderivate als aurora-a- kinaseinhibitoren

Info

Publication number
ATE428708T1
ATE428708T1 AT05785230T AT05785230T ATE428708T1 AT E428708 T1 ATE428708 T1 AT E428708T1 AT 05785230 T AT05785230 T AT 05785230T AT 05785230 T AT05785230 T AT 05785230T AT E428708 T1 ATE428708 T1 AT E428708T1
Authority
AT
Austria
Prior art keywords
aurora
new
kinase inhibitors
phthalazinone derivatives
phthalazinone
Prior art date
Application number
AT05785230T
Other languages
English (en)
Inventor
Edward Boyd
Frederick Brookfield
Guy Georges
Bernhard Goller
Sabine Huensch
Petra Rueger
Matthias Rueth
Stefan Scheiblich
Christine Schuell
Der Saal Wolfgang Von
Justin Warne
Stefan Weigand
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE428708T1 publication Critical patent/ATE428708T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05785230T 2004-09-24 2005-09-23 Neue phthalazinonderivate als aurora-a- kinaseinhibitoren ATE428708T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04022755 2004-09-24
PCT/EP2005/010311 WO2006032518A1 (en) 2004-09-24 2005-09-23 Novel phthalazinone derivatives, as aurora-a kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE428708T1 true ATE428708T1 (de) 2009-05-15

Family

ID=34926696

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05785230T ATE428708T1 (de) 2004-09-24 2005-09-23 Neue phthalazinonderivate als aurora-a- kinaseinhibitoren

Country Status (16)

Country Link
US (1) US7226923B2 (de)
EP (1) EP1794148B1 (de)
JP (1) JP2008514564A (de)
KR (1) KR100907202B1 (de)
CN (1) CN101027290B (de)
AR (1) AR050948A1 (de)
AT (1) ATE428708T1 (de)
AU (1) AU2005287458A1 (de)
BR (1) BRPI0515885A (de)
CA (1) CA2580198A1 (de)
DE (1) DE602005013985D1 (de)
ES (1) ES2323885T3 (de)
MX (1) MX2007003104A (de)
RU (1) RU2397166C2 (de)
TW (1) TW200624431A (de)
WO (1) WO2006032518A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520713A (ja) 2004-11-17 2008-06-19 ミイカナ セラピューティクス インコーポレイテッド キナーゼ阻害剤
CA2622352C (en) 2005-09-30 2014-05-27 Miikana Therapeutics, Inc. Substituted pyrazole compounds
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2009530330A (ja) * 2006-03-20 2009-08-27 エフ.ホフマン−ラ ロシュ アーゲー フタラジノンピラゾール誘導体、その製造および医薬品としての使用
CA2645583A1 (en) * 2006-03-20 2007-09-27 F. Hoffman-La Roche Ag Methods of inhibiting btk and syk protein kinases
EP2043970B1 (de) * 2006-07-05 2018-04-18 Centre National De La Recherche Scientifique (C.N.R.S.) Co-katalysiertes eisen-kupfer-verfahren für kohlenstoff-kohlenstoff- oder kohlenstoff-heteroatom-bindung
GB0619342D0 (en) * 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
DE102008000872A1 (de) 2007-04-11 2008-11-13 Basf Se Fungizide Pyridazine, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung von Schadpilzen sowie sie enthaltende Mittel
CA2829755A1 (en) 2011-03-23 2012-09-27 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
ES2648820T3 (es) * 2011-05-10 2018-01-08 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de los canales de sodio
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (de) 2011-07-01 2018-04-28
US9783529B2 (en) 2013-03-13 2017-10-10 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
US9695114B2 (en) 2013-12-18 2017-07-04 Monsanto Technology Llc Processes for the diazotization of 2,5-dichloroanilines
WO2016130460A2 (en) * 2015-02-09 2016-08-18 The Johns Hopkins University Phthalazinone pyrazole derivatives for treating retinal degenerative disease
EP3317277B1 (de) 2015-07-01 2021-01-20 Crinetics Pharmaceuticals, Inc. Somatostatinmodulatoren und verwendungen davon
RU2674761C2 (ru) * 2016-12-21 2018-12-13 федеральное государственное бюджетное образовательное учреждение высшего образования "Тольяттинский государственный университет" Способ получения анилина и катализатор для него
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
CN108250150B (zh) * 2018-03-15 2020-12-29 兰州大学 一种肽嗪酮化合物及其制备方法与应用
CN111039940B (zh) * 2019-12-31 2022-10-21 北京鑫开元医药科技有限公司 一种Aurora A激酶抑制剂、制备方法、药物组合物及其用途
CN113773263B (zh) * 2020-06-10 2023-09-19 兰州大学 一种4-胺取代酞嗪酮极光激酶b抑制剂及其制备与应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
AU686843B2 (en) 1994-02-23 1998-02-12 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US5962312A (en) 1995-12-18 1999-10-05 Sugen, Inc. Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
US6180629B1 (en) * 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
DK1553097T3 (da) 1999-02-10 2010-12-13 Astrazeneca Ab Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil
GB9922173D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CN1391562A (zh) 1999-09-21 2003-01-15 阿斯特拉曾尼卡有限公司 用作药物的喹唑啉衍生物
CZ20021010A3 (cs) 1999-09-21 2002-06-12 Astrazeneca Ab Nové sloučeniny chinazolinu a farmaceutické kompozice, které je obsahují
JP2003520855A (ja) 2000-01-28 2003-07-08 アストラゼネカ アクチボラグ 化学的化合物
AU779695B2 (en) 2000-04-07 2005-02-10 Astrazeneca Ab Quinazoline compounds
DK1318997T3 (da) 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
JP4523271B2 (ja) 2001-06-01 2010-08-11 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール化合物
CA2456985A1 (en) 2001-08-15 2003-02-27 Icos Corporation 2h-phthalazin-1-ones and methods for use thereof
ES2333702T3 (es) * 2001-12-24 2010-02-26 Astrazeneca Ab Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
RS63204A (sr) * 2002-01-17 2006-10-27 Neurogen Corporation Supstituisani analozi hinazolin-4-ilamina kao modulatori kapsaicina
ES2289279T3 (es) 2002-03-15 2008-02-01 Vertex Pharmaceuticals Incorporated Composiciones utiles como inhibidores de proteinquinasas.
EP1485100B1 (de) 2002-03-15 2010-05-05 Vertex Pharmaceuticals Incorporated Azolylaminoazine als proteinkinasehemmer
ATE433973T1 (de) 2002-03-15 2009-07-15 Vertex Pharma Azolylaminoazine als inhibitoren von proteinkinasen
ATE468336T1 (de) 2002-03-15 2010-06-15 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
WO2004005283A1 (en) 2002-07-09 2004-01-15 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities

Also Published As

Publication number Publication date
ES2323885T3 (es) 2009-07-27
CA2580198A1 (en) 2006-03-30
CN101027290B (zh) 2010-05-12
AR050948A1 (es) 2006-12-06
KR20070046193A (ko) 2007-05-02
DE602005013985D1 (de) 2009-05-28
EP1794148B1 (de) 2009-04-15
BRPI0515885A (pt) 2008-08-12
JP2008514564A (ja) 2008-05-08
RU2397166C2 (ru) 2010-08-20
KR100907202B1 (ko) 2009-07-10
US20060089359A1 (en) 2006-04-27
AU2005287458A1 (en) 2006-03-30
TW200624431A (en) 2006-07-16
EP1794148A1 (de) 2007-06-13
US7226923B2 (en) 2007-06-05
RU2007115161A (ru) 2008-11-10
MX2007003104A (es) 2007-06-07
CN101027290A (zh) 2007-08-29
WO2006032518A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
ATE428708T1 (de) Neue phthalazinonderivate als aurora-a- kinaseinhibitoren
ATE494287T1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE524467T1 (de) Neuartige aza-heterozyklen als kinase-inhibitoren
DE602007008529D1 (de) Als pi-3-kinaseinhibitoren verwendete pyrimidinderivate
DE602007014374D1 (de) Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
DE602005020465D1 (de) Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE540936T1 (de) Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
ATE492544T1 (de) Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
ATE518860T1 (de) Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE531705T1 (de) Substituierte 2-chinolyloxazole geeignet als pde4 inhibitoren
DK1737461T3 (da) Carbolin-derivater til inhibering af angiogenese
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
DE602007008837D1 (de) Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
ATE395346T1 (de) Chinazolinderivate als tyrosinkinaseinhibitoren
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
DE602007013295D1 (de) Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren
ATE412652T1 (de) Triazolopyridinylsulfanylderivate als inhibitoren der p38-map-kinase
ATE530545T1 (de) Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
ATE393159T1 (de) Heterobicyclische pyrazolderivate als kinaseinhibitoren
ATE387202T1 (de) Pyrrolidinderivate als histaminrezeptor-liganden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1794148

Country of ref document: EP